Bristol needs to get fresh

Bristol needs to get fresh

Source: 
EP Vantage
snippet: 

What was once fresh can soon become stale. This is universally true in biopharma, and at present Bristol Myers Squibb is the prime example of a group that has so far failed to find new blood to replace its ageing blockbusters.

Evaluate Vantage’s latest analysis of the freshness index, which looks at the proportion of a company’s drug sales that come from products more than 10 years old, puts Bristol at the top of this list based on 2021 revenues. And the group’s portfolio could soon look even more geriatric: these numbers do not include the PD-1 inhibitor Opdivo, which turns 10 in 2024.